Scientific deep-dive
Semaglutide for Alcohol Use Disorder: Read the Placebo Arm
Heavy drinking days fell 41.1 points on semaglutide — and 26.4 points on placebo. The drug's effect is the 13.7-point difference, and it is real, significant and a third of the number that will be quoted.
A 2026 randomized trial gave weekly semaglutide or placebo to 108 people with both alcohol use disorder and obesity. Heavy drinking days fell by 41.1 percentage points in the semaglutide group. That figure is going to travel, and it is the wrong one: the placebo group improved by 26.4 points, so the effect attributable to the drug is 13.7.[1]
The result, stated properly
| Group | Change | What it means |
|---|---|---|
| Semaglutide | −41.1 (95% CI −48.7 to −33.5) | The number that will be quoted |
| Placebo | −26.4 (95% CI −34.1 to −18.6) | The number that will not be |
| Treatment difference | −13.7 (95% CI −22.0 to −5.4), p=0.0015 | The effect of the drug |
The result is real. The confidence interval excludes zero comfortably and the trial also reported substantial effects on multiple secondary alcohol-related and physical outcomes.[1] A 13.7 point reduction in heavy drinking days is a meaningful clinical effect in a condition where treatments are few and modest.
The same trap, twice this week
This is the second trial we have written up in days where the placebo arm did most of the work in the headline number. In the fatty liver trial, steatohepatitis resolved in 62.9% on semaglutide — and in 34.3% on placebo.
When you see a single-arm percentage from a randomized trial, the other arm has been removed on purpose. Go and find it.
The pattern is worth internalizing because it is not a quirk of these two studies. Any condition where being watched helps — drinking, eating, adherence, symptom scores — will produce a large placebo response, and the drug’s contribution will be a fraction of the raw change.
How far this generalizes
- 108 participants, at a single center in Denmark. Small, and one health system.
- Everyone had obesity as well as alcohol use disorder. Whether the effect holds in people with alcohol use disorder and a normal BMI is untested, and it matters, because weight loss itself may be part of the mechanism.
- All were treatment-seeking. People who volunteer for an alcohol trial are not a random sample of people who drink heavily.
- 81% completed the intervention, which is good for this field and still leaves a fifth unaccounted for.
The direction is consistent with a growing body of preclinical and clinical work suggesting GLP-1 receptors are involved in reward and craving, which we cover in GLP-1s and substance use. Notably, a randomized trial in people who smoke missed both its primary endpoints — so this is not a uniform effect across substances.
What not to do with this
It is, though, a genuinely encouraging result in a field that badly needs them, and one worth raising with a doctor if it describes your situation.
Frequently Asked Questions
References
- 1.Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial The Lancet. 2026. PMID: 42070571.
Related research
Beyond the Scale: Blood Pressure, Lipids and What Else Changes
Pooling the individual records of 3,136 people, systolic blood pressure fell 4.95 mmHg further than placebo — and by about the same amount whether or not the person had hypertension.
7 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% were consuming below estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
GLP-1 Drugs After 65: Strength, Not Just Weight
Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite — and no guidelines exist for this age group.
7 min read
GLP-1 Drugs and Addiction: A Huge Signal, and a Trial That Missed
A 524,817-person cohort found fewer new substance use disorders of every kind measured. A randomized trial in people who smoke then missed both its primary endpoints. Both landed in 2026.
7 min read
GLP-1 Drugs and Eating Disorders: Two Questions, One Studied
Five studies covering 182 people make up the whole meta-analytic evidence base in binge eating disorder. What happens when these drugs reach someone with a restrictive eating disorder has never been studied at all.
6 min read
GLP-1 Drugs and Headache: A Side Effect, and a Treatment
Headache is in the label’s adverse reactions table at 14% against 10% on placebo. A randomized trial using implanted pressure monitors also found a GLP-1 lowered intracranial pressure within hours.
7 min read
Where to get semaglutide (Ozempic / Wegovy) online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Synergy Rx
Knowing which pharmacy fills the vial — it names Belmar Pharmacy
From $199/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $249/mo
Get started →Strut Health
Semaglutide at $99/month, 48% under the register median
From $99/mo
Get started →